Drugs Approved for Treatment of a Substance Use Disorders
CEUs: 2
Course Description:
Beginning in June 2023, dentists will be required to check a box on their online DEA registration form – regardless of whether a registrant is completing their initial registration application or renewing their registration – affirming that they have completed a new one time eight-hour training requirement. The deadline for satisfying the requirement is the date of a practitioners’ next scheduled DEA registration submission on or after June 27, 2023. This present course provides two of the eight hours of the requirement.
Learning Objectives:
After completing the course, the participants will be able to:
- Describe the rationale for using opiate medications in opioid withdrawal.
- Name the three major drugs used to treat opioid use disorder.
- For the drugs named above, describe its mechanism of action, key adverse effects and drug formulations.
- Describe the role of naloxone in the buprenorphine formulation (Suboxone).
- Describe the requirements for physicians to prescribe Suboxone in Office-based Opioid Treatment (OBOT). Also, the latest methadone/buprenorphine rule as of April 2024.
- List ten symptoms of opiate withdrawal.
Speaker:
Richard Wynn, PhD
Add to:
